Symbols / KZIA
KZIA Chart
About
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 94.95M |
| Enterprise Value | 7.54B | Income | -20.70M | Sales | 1.83M |
| Book/sh | -3.57 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | -1083.30 | PEG | — |
| P/S | 51.91 | P/B | -2.34 | P/C | — |
| EV/EBITDA | -567.36 | EV/Sales | 4120.43 | Quick Ratio | 0.32 |
| Current Ratio | 0.35 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -13.16 | EPS next Y | -0.01 | EPS Growth | — |
| Revenue Growth | -27.20% | Earnings | — | ROA | -64.28% |
| ROE | — | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -268.37% | Profit Margin | 0.00% | Shs Outstand | 11.34M |
| Shs Float | 634.49M | Short Float | 0.43% | Short Ratio | 0.22 |
| Short Interest | — | 52W High | 17.40 | 52W Low | 2.86 |
| Beta | 1.63 | Avg Volume | 231.00K | Volume | 43.52K |
| Target Price | $19.53 | Recom | None | Prev Close | $8.22 |
| Price | $8.38 | Change | 1.90% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$19.53
Mean price target
2. Current target
$8.38
Latest analyst target
3. DCF / Fair value
$-23.67
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.38
Low
$18.50
High
$20.56
Mean
$19.53
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-12-12 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-10-02 | main | Maxim Group | Buy → Buy | $20 |
| 2025-07-10 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-06-11 | main | Maxim Group | Buy → Buy | $15 |
| 2025-02-06 | init | Maxim Group | — → Buy | $3 |
| 2024-07-12 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-04-11 | up | HC Wainwright & Co. | Neutral → Buy | $2 |
| 2022-08-02 | down | Maxim Group | Buy → Hold | — |
| 2022-08-02 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2021-10-14 | init | Maxim Group | — → Buy | $18 |
| 2021-01-05 | init | HC Wainwright & Co. | — → Buy | $17 |
- Kazia Therapeutics (NASDAQ: KZIA) early data show 76% tumor shrinkage and 78% CTC cluster drop - Stock Titan Wed, 10 Dec 2025 08
- KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show? - Stocktwits Fri, 30 Jan 2026 08
- Kazia Therapeutics (KZIA) Maintained with Raised Price Target by HC Wainwright | KZIA Stock News - GuruFocus Fri, 12 Dec 2025 08
- Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline - TipRanks ue, 18 Nov 2025 08
- 12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga Wed, 04 Mar 2026 17
- Kazia Therapeutics stock price target raised to $18 from $13 at H.C. Wainwright - Investing.com Fri, 12 Dec 2025 08
- Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps - Yahoo Finance Wed, 09 Jul 2025 07
- (KZIA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily ue, 10 Feb 2026 08
- Kazia (Nasdaq: KZIA) reports iCR in metastatic TNBC and outlines Q4 oncology pipeline - Stock Titan ue, 18 Nov 2025 08
- Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data - Investing.com Fri, 30 Jan 2026 08
- What Sparked Kazia Therapeutics' Over 51% After-Hours Surge? - Benzinga Wed, 19 Nov 2025 08
- Breast cancer drug update expected this month as Kazia heads to JP Morgan - Stock Titan hu, 08 Jan 2026 08
- Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance - TipRanks Fri, 19 Dec 2025 08
- Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - Yahoo Finance ue, 02 Dec 2025 08
- Kazia stock soars after patient shows complete response in TNBC trial - Investing.com Nigeria ue, 18 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -453.07K | 1.19K | 44.28K | 217.48 |
| TaxRateForCalcs | 0.08 | 0.01 | 0.01 | 0.01 |
| NormalizedEBITDA | -7.46M | -26.71M | -25.66M | -23.55M |
| TotalUnusualItems | -5.83M | 119.00K | 3.39M | 15.00K |
| TotalUnusualItemsExcludingGoodwill | -5.83M | 119.00K | 3.39M | 15.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -20.70M | -26.78M | -20.46M | -25.01M |
| ReconciledDepreciation | 934.00K | 1.87M | 1.87M | 1.87M |
| EBITDA | -13.28M | -26.59M | -22.28M | -23.53M |
| EBIT | -14.22M | -28.46M | -24.15M | -25.40M |
| NetInterestIncome | 72.00K | 12.00K | 22.00K | 2.00K |
| InterestIncome | 72.00K | 12.00K | 22.00K | 2.00K |
| NormalizedIncome | -15.33M | -26.90M | -23.81M | -25.03M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -20.70M | -26.78M | -20.46M | -25.01M |
| TotalExpenses | 14.26M | 30.77M | 24.15M | 25.40M |
| DilutedAverageShares | 527.35K | 368.57K | 264.94K | 235.35K |
| BasicAverageShares | 527.35K | 368.57K | 264.94K | 235.35K |
| DilutedEPS | -50.80 | -56.15 | -93.05 | -35.80 |
| BasicEPS | -50.80 | -56.15 | -93.05 | -35.80 |
| DilutedNIAvailtoComStockholders | -20.70M | -26.78M | -20.46M | -25.01M |
| NetIncomeCommonStockholders | -20.70M | -26.78M | -20.46M | -25.01M |
| NetIncome | -20.70M | -26.78M | -20.46M | -25.01M |
| NetIncomeIncludingNoncontrollingInterests | -20.70M | -26.78M | -20.46M | -25.01M |
| NetIncomeContinuousOperations | -20.70M | -26.78M | -20.46M | -25.01M |
| TaxProvision | -1.75M | -271.00K | -271.00K | -368.00K |
| PretaxIncome | -22.45M | -27.05M | -20.74M | -25.38M |
| OtherIncomeExpense | -8.30M | 1.40M | 3.39M | 15.00K |
| OtherNonOperatingIncomeExpenses | -2.48M | 1.28M | 1.00K | |
| SpecialIncomeCharges | -5.83M | 119.00K | 3.39M | 15.00K |
| GainOnSaleOfPPE | 0.00 | |||
| WriteOff | 0.00 | 0.00 | -15.00K | 0.00 |
| ImpairmentOfCapitalAssets | 13.38M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | -7.55M | -119.00K | -3.39M | 0.00 |
| NetNonOperatingInterestIncomeExpense | 72.00K | 12.00K | 22.00K | 2.00K |
| InterestIncomeNonOperating | 72.00K | 12.00K | 22.00K | 2.00K |
| OperatingIncome | -14.22M | -28.46M | -24.15M | -25.40M |
| OperatingExpense | 14.26M | 30.77M | 24.15M | 25.40M |
| OtherOperatingExpenses | -1.79M | -173.00K | -1.00K | -10.00K |
| OtherTaxes | 0.00 | 0.00 | -2.00K | |
| ResearchAndDevelopment | 7.33M | 17.38M | 15.56M | 20.17M |
| SellingGeneralAndAdministration | 8.72M | 13.56M | 8.58M | 5.24M |
| SellingAndMarketingExpense | 0.00 | 0.00 | 127.00K | 0.00 |
| GeneralAndAdministrativeExpense | 8.72M | 13.56M | 8.58M | 5.11M |
| OtherGandA | 8.72M | 13.56M | 8.58M | 5.11M |
| TotalRevenue | 42.00K | 2.31M | 0.00 | 0.00 |
| OperatingRevenue | 42.00K | 2.31M | 0.00 | 0.00 |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 809.42M | 332.85M | 228.03M | 138.76M |
| ShareIssued | 809.42M | 332.85M | 228.03M | 138.76M |
| TotalDebt | 396.00K | 634.00K | 1.80M | 1.84M |
| TangibleBookValue | -9.39M | -25.42M | -5.22M | -864.00K |
| InvestedCapital | -7.91M | -9.38M | 13.85M | 20.12M |
| WorkingCapital | -9.12M | -19.65M | 3.21M | 2.72M |
| NetTangibleAssets | -9.39M | -25.42M | -5.22M | -864.00K |
| CommonStockEquity | -8.30M | -10.02M | 12.05M | 18.27M |
| TotalCapitalization | -8.30M | -10.02M | 12.05M | 18.27M |
| TotalEquityGrossMinorityInterest | -8.30M | -10.02M | 12.05M | 18.27M |
| StockholdersEquity | -8.30M | -10.02M | 12.05M | 18.27M |
| OtherEquityInterest | 464.00K | |||
| GainsLossesNotAffectingRetainedEarnings | 3.10M | 3.48M | 3.68M | 2.41M |
| RetainedEarnings | -134.83M | -115.13M | -89.08M | -68.62M |
| AdditionalPaidInCapital | 380.00K | 0.00 | 0.00 | 0.00 |
| CapitalStock | 123.05M | 101.64M | 97.45M | 84.48M |
| CommonStock | 123.05M | 101.64M | 97.45M | 84.48M |
| TotalLiabilitiesNetMinorityInterest | 14.36M | 31.60M | 16.03M | 17.61M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 309.00K | 5.80M | 8.47M | 10.89M |
| OtherNonCurrentLiabilities | 3.75M | 6.12M | 8.21M | 10.30M |
| EmployeeBenefits | 37.00K | 35.00K | 59.00K | 117.00K |
| NonCurrentDeferredLiabilities | 272.00K | 2.02M | 2.29M | 2.56M |
| NonCurrentDeferredTaxesLiabilities | 272.00K | 2.02M | 2.29M | 2.56M |
| CurrentLiabilities | 14.05M | 25.80M | 7.57M | 6.73M |
| OtherCurrentLiabilities | 3.15M | 9.73M | 750.00K | 759.00K |
| CurrentDebtAndCapitalLeaseObligation | 396.00K | 634.00K | 1.80M | 1.84M |
| CurrentDebt | 396.00K | 634.00K | 1.80M | 1.84M |
| OtherCurrentBorrowings | 396.00K | 634.00K | 1.80M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 390.00K | 365.00K | 690.00K | 369.00K |
| PayablesAndAccruedExpenses | 10.12M | 15.07M | 4.33M | 3.76M |
| CurrentAccruedExpenses | 4.47M | 10.52M | 3.47M | 2.23M |
| Payables | 5.64M | 4.55M | 857.00K | 1.52M |
| OtherPayable | 2.24M | 3.04M | ||
| AccountsPayable | 5.64M | 4.55M | 857.00K | 1.52M |
| TotalAssets | 6.06M | 21.59M | 28.08M | 35.89M |
| TotalNonCurrentAssets | 1.13M | 15.44M | 17.31M | 26.44M |
| NonCurrentPrepaidAssets | 40.00K | 40.00K | 43.00K | 7.30M |
| GoodwillAndOtherIntangibleAssets | 1.09M | 15.40M | 17.27M | 19.14M |
| OtherIntangibleAssets | 1.09M | 15.40M | 17.27M | 19.14M |
| CurrentAssets | 4.93M | 6.14M | 10.77M | 9.45M |
| OtherCurrentAssets | 1.72M | |||
| PrepaidAssets | 499.00K | 4.36M | 5.43M | 2.04M |
| Receivables | 90.00K | 133.00K | 105.00K | 51.00K |
| OtherReceivables | 90.00K | 133.00K | 104.00K | 51.00K |
| TaxesReceivable | 0.00 | |||
| AccountsReceivable | 0.00 | 1.00K | 0.00 | 84.00K |
| CashCashEquivalentsAndShortTermInvestments | 4.34M | 1.66M | 5.24M | 7.36M |
| CashAndCashEquivalents | 4.34M | 1.66M | 5.24M | 7.36M |
| CashEquivalents | 0.00 | 6.50M | ||
| CashFinancial | 4.34M | 1.66M | 5.24M | 7.36M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -13.28M | -9.58M | -15.16M | -22.76M |
| RepaymentOfDebt | 0.00 | -371.00K | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 776.00K | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 14.80M | 5.58M | 12.97M | 3.73M |
| EndCashPosition | 4.34M | 1.66M | 5.24M | 7.36M |
| BeginningCashPosition | 1.66M | 5.24M | 7.36M | 27.59M |
| EffectOfExchangeRateChanges | -16.00K | 12.00K | 64.00K | 1.18M |
| ChangesInCash | 2.70M | -3.60M | -2.18M | -21.40M |
| FinancingCashFlow | 15.98M | 5.99M | 12.97M | 3.73M |
| CashFlowFromContinuingFinancingActivities | 15.98M | 5.99M | 12.97M | 3.73M |
| ProceedsFromStockOptionExercised | 1.18M | 0.00 | 0.00 | |
| NetCommonStockIssuance | 14.80M | 5.58M | 12.97M | 3.73M |
| CommonStockIssuance | 14.80M | 5.58M | 12.97M | 3.73M |
| NetIssuancePaymentsOfDebt | 0.00 | 405.00K | 0.00 | 0.00 |
| NetShortTermDebtIssuance | 0.00 | 405.00K | 0.00 | 0.00 |
| ShortTermDebtPayments | 0.00 | -371.00K | 0.00 | 0.00 |
| ShortTermDebtIssuance | 0.00 | 776.00K | 0.00 | 0.00 |
| InvestingCashFlow | 0.00 | 0.00 | -2.37M | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | 0.00 | -2.37M | 0.00 |
| NetOtherInvestingChanges | -2.37M | |||
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| NetBusinessPurchaseAndSale | -2.37M | 0.00 | ||
| PurchaseOfBusiness | -2.37M | 0.00 | ||
| OperatingCashFlow | -13.28M | -9.58M | -15.16M | -22.76M |
| CashFlowFromContinuingOperatingActivities | -13.28M | -9.58M | -15.16M | -22.76M |
| ChangeInWorkingCapital | -3.01M | 10.00M | 4.33M | 862.00K |
| ChangeInOtherWorkingCapital | -1.72M | -620.00K | -7.00K | -167.00K |
| ChangeInOtherCurrentLiabilities | -238.00K | -1.16M | -45.00K | 1.84M |
| ChangeInOtherCurrentAssets | 100.00K | 1.04M | 365.00K | -277.00K |
| ChangeInPayablesAndAccruedExpense | -4.95M | 10.74M | 569.00K | -528.00K |
| ChangeInPayable | -4.95M | 10.74M | 569.00K | -528.00K |
| ChangeInPrepaidAssets | 365.00K | 1.56M | -1.18M | |
| ChangeInReceivables | 3.80M | 5.00K | 3.45M | -7.00K |
| ChangesInAccountReceivables | 3.80M | 5.00K | 3.45M | -6.00K |
| OtherNonCashItems | -5.83M | 6.09M | -2.10M | 152.00K |
| StockBasedCompensation | 653.00K | 533.00K | 1.16M | 1.68M |
| UnrealizedGainLossOnInvestmentSecurities | 982.00K | -1.28M | 0.00 | 0.00 |
| AssetImpairmentCharge | 13.38M | 0.00 | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 934.00K | 1.87M | 1.87M | 1.87M |
| DepreciationAndAmortization | 934.00K | 1.87M | 1.87M | 1.87M |
| AmortizationCashFlow | 934.00K | 1.87M | 1.87M | 1.87M |
| AmortizationOfIntangibles | 934.00K | 1.87M | 1.87M | 1.87M |
| OperatingGainsLosses | 310.00K | -20.00K | 46.00K | -2.15M |
| NetForeignCurrencyExchangeGainLoss | 310.00K | -20.00K | 46.00K | -2.15M |
| NetIncomeFromContinuingOperations | -20.70M | -26.78M | -20.46M | -25.01M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KZIA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|